Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and Tiara, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe.
Company profile
Ticker
NVCN
Exchange
Website
CEO
Fred Colen
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Medical Ventures Corp
SEC CIK
NVCN stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
3 Aug 23
15F-12B
Securities registration termination (foreign)
24 Apr 23
6-K
Current report (foreign)
12 Apr 23
6-K
Current report (foreign)
11 Apr 23
RW
Registration withdrawal request
11 Apr 23
F-10POS
Automatic registration of securities (post-effective amendment, Canada)
11 Apr 23
POS AM
Prospectus update (post-effective amendment)
11 Apr 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Apr 23
25-NSE
Exchange delisting
11 Apr 23
6-K
Shockwave Medical Completes Acquisition of Neovasc
11 Apr 23
Transcripts
NVCN
Earnings call transcript
2022 Q3
11 Nov 22
NVCN
Earnings call transcript
2022 Q2
12 Aug 22
NVCN
Earnings call transcript
2022 Q1
13 May 22
NVCN
Earnings call transcript
2021 Q3
10 Nov 21
NVCN
Earnings call transcript
2021 Q2
11 Aug 21
NVCN
Earnings call transcript
2021 Q1
7 May 21
NVCN
Earnings call transcript
2020 Q4
12 Mar 21
NVCN
Earnings call transcript
2020 Q3
8 Nov 20
Latest ownership filings
SC 13G/A
CVI Investments, Inc.
14 Feb 22
SC 13D
FiveT Investment Management Ltd
25 Feb 21
SC 13G
INTRACOASTAL CAPITAL, LLC
19 Feb 21
SC 13G
CVI Investments, Inc.
19 Feb 21
SC 13G/A
Magnetar Financial LLC
12 Feb 21
SC 13G/A
SABBY MANAGEMENT, LLC
6 Jan 21
SC 13G
INTRACOASTAL CAPITAL, LLC
17 Dec 20
SC 13G
ARMISTICE CAPITAL, LLC
20 Aug 20
SC 13G
Strul Medical Group, LLC
29 Jun 20
SC 13G
ARMISTICE CAPITAL, LLC
22 Jun 20
Financial summary
Quarter (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q4 2022
13F holders | Current |
---|---|
Total holders | 13 |
Opened positions | 3 |
Closed positions | 2 |
Increased positions | 2 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 2.19 bn |
Total shares | 16.90 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
BSX Boston Scientific | 11.82 mm | $720.84 mm |
CVI Investments | 2.56 mm | $0.00 |
Intracoastal Capital | 2.41 mm | $4.82 mm |
Natixis | 49.78 k | $790.97 mm |
U.S. Capital Wealth Advisors | 18.78 k | $296.63 mm |
Magnetar Financial | 15.80 k | $245.00 k |
RSM Us Wealth Management | 12.44 k | $229.89 mm |
MS Morgan Stanley | 3.64 k | $57.42 mm |
BAC Bank Of America | 2.70 k | $42.66 mm |
RY Royal Bank Of Canada | 1.59 k | $25.00 mm |